Back to search
FDAFDA · Food and drugs·Recall number D-0040-2027

Tirzepatide/Niacinamide 2mL vial (40 MG per Vial) Inj 20mg/2mg/mL, RX Only, Houston RX LLC, 15430 Vantage Parkway E STE 220, Houston, TX 77032.

Published October 21, 2026 · Recall initiated: September 25, 2026

Summary

FDA records drug Class II recall D-0040-2027, published October 21, 2026 and initiated September 25, 2026. Recalling firm: Houston Rx LLC; Status: Ongoing; Reported quantity: 64 vials; Lot: Lot# TZN-080326-20/2-2, Beyond Use Date: 12/01/2026. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Lack of assurance of sterility.

What to do

Voluntary: Firm initiated · Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Houston Rx LLC
Distributor
Nationwide in the USA.
Lot
Lot# TZN-080326-20/2-2, Beyond Use Date: 12/01/2026.
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Tirzepatide/Niacinamide 2mL vial (40 MG per Vial) Inj 20mg/2mg/mL, RX Only, Houston RX LLC, 15430 Vantage Parkway E STE 220, Houston, TX 77032. recalled?

Yes. FDA published recall D-0040-2027 on October 21, 2026. Reported hazard: Lack of assurance of sterility.

What should I do if I have this product?

Voluntary: Firm initiated · Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit